Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1994 Dec;38(12):2846–2849. doi: 10.1128/aac.38.12.2846

Simulation of amoxicillin pharmacokinetics in humans for the prevention of streptococcal endocarditis in rats.

U Fluckiger 1, P Moreillon 1, J Blaser 1, M Bickle 1, M P Glauser 1, P Francioli 1
PMCID: PMC188295  PMID: 7695272

Abstract

The pharmacokinetic determinants of successful antibiotic prophylaxis of endocarditis are not precisely known. Differences in half-lives of antibiotics between animals and humans preclude extrapolation of animal results to human situations. To overcome this limitation, we have mimicked in rats the amoxicillin kinetics in humans following a 3-g oral dose (as often used for prophylaxis of endocarditis) by delivering the drug through a computerized pump. Rats with catheter-induced vegetations were challenged with either of two strains of antibiotic-tolerant viridans group streptococci. Antibiotics were given either through the pump (to simulate the whole kinetic profile during prophylaxis in humans) or as an intravenous bolus which imitated only the peak level of amoxicillin (18 mg/liter) in human serum. Prophylaxis by intravenous bolus was inoculum dependent and afforded a limited protection only in rats challenged with the minimum inoculum size infecting > or = 90% of untreated controls. In contrast, simulation of kinetics in humans significantly protected animals challenged with 10 to 100 times the inoculum of either of the test organisms infecting > or = 90% of untreated controls. Thus, simulation of the profiles of amoxicillin prophylaxis in human serum was more efficacious than mere imitation of the transient peak level in rats. This confirms previous studies suggesting that the duration for which the serum amoxicillin level remained detectable (not only the magnitude of the peak) was an important parameter in successful prophylaxis of endocarditis. The results also suggest that single-dose prophylaxis with 3 g of amoxicillin in humans might be more effective than predicted by conventional animal models in which only peak levels of antibiotic in human serum were stimulated.

Full text

PDF
2846

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antibiotic prophylaxis for patients with prosthetic valves. Lancet. 1983 Jan 29;1(8318):237–238. [PubMed] [Google Scholar]
  2. Antibiotic prophylaxis of infective endocarditis. Recommendations from the Endocarditis Working Party of the British Society for Antimicrobial Chemotherapy. Lancet. 1990 Jan 13;335(8681):88–89. [PubMed] [Google Scholar]
  3. Bayer A. S., Tu J. Chemoprophylactic efficacy against experimental endocarditis caused by beta-lactamase-producing, aminoglycoside-resistant enterococci is associated with prolonged serum inhibitory activity. Antimicrob Agents Chemother. 1990 Jun;34(6):1068–1074. doi: 10.1128/aac.34.6.1068. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Dajani A. S., Bisno A. L., Chung K. J., Durack D. T., Freed M., Gerber M. A., Karchmer A. W., Millard H. D., Rahimtoola S., Shulman S. T. Prevention of bacterial endocarditis. Recommendations by the American Heart Association. JAMA. 1990 Dec 12;264(22):2919–2922. [PubMed] [Google Scholar]
  5. Fluckiger U., Francioli P., Blaser J., Glauser M. P., Moreillon P. Role of amoxicillin serum levels for successful prophylaxis of experimental endocarditis due to tolerant streptococci. J Infect Dis. 1994 Jun;169(6):1397–1400. doi: 10.1093/infdis/169.6.1397. [DOI] [PubMed] [Google Scholar]
  6. Gerber A. U., Brugger H. P., Feller C., Stritzko T., Stalder B. Antibiotic therapy of infections due to Pseudomonas aeruginosa in normal and granulocytopenic mice: comparison of murine and human pharmacokinetics. J Infect Dis. 1986 Jan;153(1):90–97. doi: 10.1093/infdis/153.1.90. [DOI] [PubMed] [Google Scholar]
  7. Glauser M. P., Bernard J. P., Moreillon P., Francioli P. Successful single-dose amoxicillin prophylaxis against experimental streptococcal endocarditis: evidence for two mechanisms of protection. J Infect Dis. 1983 Mar;147(3):568–575. doi: 10.1093/infdis/147.3.568. [DOI] [PubMed] [Google Scholar]
  8. Meier B., Lüthy R., Siegenthaler W. Endokarditis-Prophylaxe mit Amoxycillin, Clindamycin oder Erythromycin Eine pharmakokinetische Betrachtung. Schweiz Med Wochenschr. 1984 Sep 15;114(37):1252–1256. [PubMed] [Google Scholar]
  9. Meylan P. R., Francioli P., Glauser M. P. Discrepancies between MBC and actual killing of viridans group streptococci by cell-wall-active antibiotics. Antimicrob Agents Chemother. 1986 Mar;29(3):418–423. doi: 10.1128/aac.29.3.418. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Mizen L., Woodnutt G. A critique of animal pharmacokinetics. J Antimicrob Chemother. 1988 Mar;21(3):273–278. doi: 10.1093/jac/21.3.273. [DOI] [PubMed] [Google Scholar]
  11. Moreillon P., Francioli P., Overholser D., Meylan P., Glauser M. P. Mechanisms of successful amoxicillin prophylaxis of experimental endocarditis due to Streptococcus intermedius. J Infect Dis. 1986 Nov;154(5):801–807. doi: 10.1093/infdis/154.5.801. [DOI] [PubMed] [Google Scholar]
  12. Sabath L. D., Wheeler N., Laverdiere M., Blazevic D., Wilkinson B. J. A new type of penicillin resistance of Staphylococcus aureus. Lancet. 1977 Feb 26;1(8009):443–447. doi: 10.1016/s0140-6736(77)91941-9. [DOI] [PubMed] [Google Scholar]
  13. Shanson D. C., Ashford R. F., Singh J. High-dose oral amoxycillin for preventing endocarditis. Br Med J. 1980 Feb 16;280(6212):446–446. doi: 10.1136/bmj.280.6212.446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Thauvin C., Eliopoulos G. M., Willey S., Wennersten C., Moellering R. C., Jr Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats. Antimicrob Agents Chemother. 1987 Feb;31(2):139–143. doi: 10.1128/aac.31.2.139. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Van der Meer J. T., Van Wijk W., Thompson J., Vandenbroucke J. P., Valkenburg H. A., Michel M. F. Efficacy of antibiotic prophylaxis for prevention of native-valve endocarditis. Lancet. 1992 Jan 18;339(8786):135–139. doi: 10.1016/0140-6736(92)90207-j. [DOI] [PubMed] [Google Scholar]
  16. Woodnutt G., Catherall E. J., Kernutt I., Mizen L. Temocillin efficacy in experimental Klebsiella pneumoniae meningitis after infusion into rabbit plasma to simulate antibiotic concentrations in human serum. Antimicrob Agents Chemother. 1988 Nov;32(11):1705–1709. doi: 10.1128/aac.32.11.1705. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Yeaman M. R., Norman D. C., Bayer A. S. Platelet microbicidal protein enhances antibiotic-induced killing of and postantibiotic effect in Staphylococcus aureus. Antimicrob Agents Chemother. 1992 Aug;36(8):1665–1670. doi: 10.1128/aac.36.8.1665. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Yeaman M. R., Sullam P. M., Dazin P. F., Norman D. C., Bayer A. S. Characterization of Staphylococcus aureus-platelet binding by quantitative flow cytometric analysis. J Infect Dis. 1992 Jul;166(1):65–73. doi: 10.1093/infdis/166.1.65. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES